Latest
FDA panel votes 8-6 to loosen peptide rules/FDA panel votes 8-6 to loosen peptide rules/FDA panel votes 8-6 to loosen peptide rules/FDA panel votes 8-6 to loosen peptide rules/
← Wellness
Longevity · Jul 25, 2026 · 4 min read

The FDA Just Legalized the Peptide Menu. Trust Is the Only Thing You Still Have to Earn.

An FDA advisory panel voted 8 to 6 to let compounding pharmacies make four popular peptides, clearing a path for every wellness operator to bolt on a peptide menu. The ones who win will not be the ones who sell it fastest. They will be the ones members trust enough to say no.

Alice covers growth, retention and technology for fitness and wellness operators at The Run Rate.

Editorial collage of a vial and syringe on a torn paper shape beside a hand-drawn balance scale weighing access against trust, navy, butter and cream palette
Make The Run Rate one of your go-to sources on Google Add The Run Rate on Google
8-6
FDA advisory committee vote
4
Peptides cleared for compounding
2-day
Pharmacy Compounding Advisory review

An FDA advisory panel spent two days in late July reviewing the most popular injectable peptides, and by the end it voted 8 to 6 that four of them can be safely produced by compounding pharmacies. That reverses Biden-era restrictions that had kept these substances in a regulatory grey zone. For the longevity industry, this is the starting gun. Every med spa, recovery lounge, and wellness-forward studio now has a clear path to a peptide menu, and a lot of them are going to sprint for it.

Here is why you should slow down before you do. Peptides (short chains of amino acids marketed for recovery, muscle, and anti-aging effects) are about to go from something operators quietly sourced offshore to something they can advertise on the wall. The proponents' own argument for the change, reported by NPR and CBS News, was that prohibition had fueled a grey market of unvetted overseas suppliers. The vote does not make peptides proven. It makes them legal to compound. Those are different things, and members will not know the difference. You will have to.

Before the voteAfter the vote
Supply channelOverseas grey marketRegulated compounding pharmacy
Operator postureQuiet, deniablePublic, promotable
Member's questionWhere did this come from?Should I trust you to sell it?

Should studios add a peptide program?

Only if they can answer for it. The regulatory green light removes the sourcing excuse, not the responsibility. A wellness operator selling injectables is making an implicit health claim, and the member is buying the operator's judgment as much as the vial. If you cannot staff qualified oversight, explain the evidence honestly, and turn away the member for whom it is a bad idea, you are not offering a service. You are offering liability with a markup. The safe answer for most studios is a referral relationship, not an in-house counter.

Access just got commoditized. Judgment did not. The operators who win the longevity layer are the ones a member believes when they say this one is not for you.

— The Run Rate

This is the same pattern we traced with Oura and Eli Lilly. When the product itself becomes easy to get, the defensible layer moves to interpretation, to the trusted human who tells you what to do with it. Peptides are about to prove it in the most literal way. When everyone can sell the injection, the only differentiator left is whether members believe your reason for selling it, or for not.

We have argued that the longevity coach is becoming the new personal trainer and that longevity clinics are already coming for your members. This vote accelerates both. The clinics will move first and hardest, because peptides fit their model and their liability coverage. Boutique studios that chase them on product will lose, because a studio cannot out-clinic a clinic. What a studio can own is the relationship of trust that makes a member ask you first. Protect that, and you can refer the peptide out and keep the member. Sell the peptide badly, and you lose both. The market for peptides just opened. The market for trust was always the one worth winning.

Frequently Asked Questions

What did the FDA panel actually decide about peptides?
An FDA advisory committee voted 8-6 to add four popular injectable peptides to the list of substances that compounding pharmacies can produce, easing prior restrictions. It is a recommendation that clears a regulatory path, not a finding that the peptides are proven effective.
Should a boutique studio start selling peptides?
For most, a referral relationship with a qualified clinic is safer than an in-house program. Selling injectables carries real liability and an implicit health claim, and requires qualified oversight and honest evidence conversations.
Why is trust the real advantage here?
Once peptides are legal to compound, access is commoditized and every operator can offer them. The lasting differentiator is whether members trust your judgment about what to use and what to avoid.
More from The Run Rate